N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:	
Tai-Wha CHUNG et al.	
Application No.: 10/540,848	Group Art Unit: 1645
Confirmation No. 2217	
Filed: June 27, 2005	Examiner:

For: Monoclonal Antibody Against Asialo Alpha 1-Acid Glycoprotein, Immunochromatographic Strip Comprising The Monoclonal Antibody, And Method For Diagnosing Liver Diseases

Using The Immunochromatographic Strip

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 CFR § 1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application.

	•	•	rial to the examination of the subject application.
1.	Е	nclosures	accompanying this Information Disclosure Statement are:
		1a. [] 1b. []	Form PTO-1449. Copy(ies) of IDS citation(s), except for U.S. Patents and U.S. Patent Application publications.
		1c. 🛚	English language copy of a communication(s) from a foreign Patent Office or a PCT International Search Report.
		1d. 🔲	English language translation (complete, Abstract or relevant portion(s)) attached to non-English language publications as indicated on the attached Form PTO-1449.
		1e. 🗌	Explanations of Relevancy of References (ATTACHMENT 1(e), hereto) for providing a concise explanation of non-English publications.
		1f. 🔲	List of Copending Applications (ATTACHMENT 1(f), hereto).
		1g. 🔯	List of Additional Submitted Documents (ATTACHMENT 1(g), hereto).
2.	\boxtimes	This Infor	mation Disclosure Statement is filed under 37 CFR § 1.97(b): (Check either Item 2a or 2b or 2c or 2d)
		2a.	Within three months of the filing date of a national application; Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application.
		2c. 🛚	Before the mailing of a first Office Action on the merits; or

Serial No.: 10/540,848

	2d. 🗌	Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
3.	specified Action und	mation Disclosure Statement is filed under 37 CFR § 1.97(c) after the period in paragraph 2 above but before the mailing date of any of a Final Office der § 1.113, a Notice of Allowance under § 1.311 or an action that otherwise esecution in the application, AND (Check either Item 3a or 3b; Item 3b to be checked if any reference known for more than 3 months)
	3a.	The § 1.97(e) Statement in Item 5 below is applicable; OR The \$180.00 fee set forth in 37 CFR § 1.17(p) is: ———————————————————————————————————
		to be charged to Deposit Account No. 19-3935.
4.		mation Disclosure Statement is filed under 37 CFR § 1.97(d) after the period in paragraph 3 above, but on or before payment of the Issue Fee, AND
	4a.	The § 1.97(e) Statement in Item 5 below is applicable; AND The \$180.00 fee set forth in 37 CFR § 1.17(p) is: enclosed.
		to be charged to Deposit Account No. 19-3935.
5.	Statemen	t under § 1.97(e) (applicable if Item 3a or Item 4a is checked)
		(Check either Item 5a or 5b)
	5a. 🗌	In accordance with 37 CFR § 1.97(e)(1), it is stated that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
	5b. 🗌	In accordance with 37 CFR § 1.97(e)(2), it is stated that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known by any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
6.	This is a 0 1.53(b).	continuation/divisional/continuation-in-part application under 37 CFR §
		(Check appropriate Items 6a and/or 6b)
	6a. 🗌	Copies of the publications listed on the attached Form PTO-1449 which were previously cited in prior application Serial No, filed on, and which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, have been omitted pursuant to 37 CFR §
	6b. 🗌	1.98(d). Copies of the publications listed on the attached Form PTO-1449 which were not previously cited in prior application Serial No, filed on, and

Serial No.: 10/540,848

which is relied on for an earlier effective filing date for the subject application under 35 U.S.C. § 120, are provided herewith.

	_			
7.		This	s is a	Request for Continued Examination under 37 CFR § 1.114.
		_		(Check either Item 7a or 7b)
		7a.	_	The Issue Fee has not been paid.
		7b.		A Petition to Withdraw from issue under 37 CFR § 1.313(c) is filed
				concurrently herewith or has been granted. A Request for Continued
				Examination under 37 CFR § 1.114, after payment of the Issue Fee, is
				proper in accordance with 37 CFR § 1.114(a), respectively.
8.		This	s is a	Supplemental Information Disclosure Statement.
				(Check either Item 8a or 8b)
		8a.		This Supplemental Information Disclosure Statement under 37 CFR §
				1.97(f) supplements the Information Disclosure Statement filed on A
				bona fide attempt was made to comply with 37 CFR § 1.98, but inadvertent
				omissions were made. These omissions have been corrected herein.
				Accordingly, additional time is requested so that this Supplemental IDS can
				be considered as if properly filed on
		8b.		This Supplemental Information Disclosure Statement is timely filed within
				one (1) month of the Notice under 37 CFR §§ 1.97 and 1.98, mailed
9.	Пι	n ac	corda	nce with 37 CFR § 1.98, a concise explanation of what is presently
				I to be the relevance of each non-English language publication is:
				(Check appropriate Items 9a, 9b, 9c and/or 9d)
		92		satisfied for the non-English language publication(s) cited on the enclosed
		Ja.	لــا	"English language version of the search report or action which indicates the
				degree of relevance found by the foreign office". (See MPEP § 609,
				Minimum Requirements for an Information Disclosure Statement, Part A(3):
				Concise Explanation of Relevance, 8th Ed., Rev. 2)
		9b.		set forth in the application.
		9c.		satisfied for the non-English language publication(s) indicated on the
				attached Form PTO-1449 as having an English language translation
				(complete or relevant portion(s)) attached thereto.
		9d.		enclosed as Attachment 1(e), hereto.
10.	N	o adı	missio	on is made that the information cited in this Statement is, or is considered to
				to patentability nor a representation that a search has been made (other than
				rt(s) from a counterpart foreign application or a PCT International Search
	R	epor	t, if su	ibmitted herewith). 37 CFR §§ 1.97(g) and (h).

Serial No.: 10/540,848

11. The Commissioner is authorized to credit any overpayment or charge any additional fee required under 37 CFR § 1.17 for this Information Disclosure Statement to Deposit Account No. 19-3935.


Respectfully submitted,

STAAS & HALSEY LLP

1201 New York Ave., N.W., 7th Floor Washington, D.C. 20005

Washington, D.C. 20005 Telephone: (202) 434-1500 Facsimile: (202) 434-1501 By:

Darleen J. Stockley Registration No. 34,257



LIST OF ADDITIONAL SUBMITTED DOCUMENTS

	ALIACINILIA I I(G)
ATTORNEY DOCKET NO.	APPLICATION NO.
1877.1001	10/540,848
FIRST NAMED INVENTOR	
Tai-Wha CHUNG et al.	
FILING DATE	GROUP ART UNIT
June 27, 2005	1645

The following document(s) is/are listed in accordance with the duty of disclosure provisions of 37 CFR § 1.56, so that the Examiner may consider same should he deem any thereof to be material to examination of the subject application.

It is requested that the Examiner acknowledge his consideration of document(s) below-listed by initialling same in the space provided adjacent each such application and that the Examiner sign and date this form at the bottom thereof to confirm such consideration having been given.

This submission in no way represents an admission that any of the information listed herein constitutes prior art with respect to the subject application; and unless and until such prior art status is established, this submission is not a request that the information presented herein be printed on the face of any patent issuing from the subject application in which this information is being filed.

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA				·		
	AB						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSL YES	ATION NO
AC							
AC	D						

(THER DOCUME	NTS (Including Author, Title, Date, Pertinent Pages, Etc.)	TRANSL YES	ATION NO
	AE	Indian Office Action for corresponding India patent application no. 1296/KOL-NP/2005 dated October 11, 2006 (in English)		
	AF	Chinese Office Action for corresponding Chinese patent application no. 200380107725 dated December 8, 2006 (in English)		

EXAMINER	DATE CONSIDERED				
*EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					